Researchers propose ventilatory burden (VB) as an automated measure of obstructive sleep apnea severity and a predictor of cardiovascular disease and any-cause mortality.
Voxzogo given green-light to treat children under five by US FDA –
At present Voxzogo is currently marketed in the European Union in children with achondroplasia who are 2 years of age and older with open growth